Guardant Health (NASDAQ:GH) CTO Sells $1,435,266.56 in Stock

Guardant Health, Inc. (NASDAQ:GH) CTO Darya Chudova sold 13,664 shares of Guardant Health stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56. Following the completion of the sale, the chief technology officer directly owned 54,480 shares in the company, valued at $5,722,579.20. This represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Darya Chudova also recently made the following trade(s):

• On Monday, December 8th, Darya Chudova sold 9,271 shares of Guardant Health stock. The shares were sold at an average price of $106.00, for a total value of $982,726.00.

Guardant Health Trading Down 0.6%

GH stock traded down $0.59 during midday trading on Wednesday, reaching $102.62. The stock had a trading volume of 1,913,708 shares, compared to its average volume of 2,231,505. The company’s fifty day simple moving average is $87.13 and its 200 day simple moving average is $64.63. The company has a market cap of $12.93 billion, a price-to-earnings ratio of -31.97 and a beta of 1.58. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.88) EPS. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Leerink Partners increased their price objective on shares of Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Morgan Stanley upped their price target on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Wells Fargo & Company assumed coverage on Guardant Health in a research note on Monday, September 22nd. They set an “overweight” rating and a $72.00 price objective on the stock. Finally, Canaccord Genuity Group set a $100.00 target price on Guardant Health in a report on Thursday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $80.86.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Sound Income Strategies LLC purchased a new position in Guardant Health in the third quarter worth approximately $38,000. IFP Advisors Inc raised its position in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares during the period. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Guardant Health by 358.4% during the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the period. Finally, Optiver Holding B.V. grew its holdings in shares of Guardant Health by 153.5% during the 3rd quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after purchasing an additional 465 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.